Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 453497, 9 pages
http://dx.doi.org/10.1155/2014/453497
Research Article

Effects of Single or Combined Treatments with Radiation and Chemotherapy on Survival and Danger Signals Expression in Glioblastoma Cell Lines

1Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Via Ferrata 9, 27100 Pavia, Italy
2Department of Medical Physics, IRCCS Policlinico S. Matteo Foundation, Viale Golgi 19, 27100 Pavia, Italy
3Department of Earth and Environmental Sciences, University of Pavia, Via Ferrata 1, 27100 Pavia, Italy

Received 5 April 2014; Accepted 10 June 2014; Published 1 July 2014

Academic Editor: Zhen Chen

Copyright © 2014 Francesca Pasi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. Virrey, E. B. Golden, W. Sivakumar et al., “Glioma-associated endothelial cells are chemoresistant to temozolomide,” Journal of Neuro-Oncology, vol. 95, no. 1, pp. 13–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Ichimura, H. Ohgaki, P. Kleihues, and V. P. Collins, “Molecular pathogenesis of astrocytic tumours,” The Journal of Neuro-Oncology, vol. 70, no. 2, pp. 137–160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Han, S. Chen, K. N. Yu, and L. Wu, “Nitric oxide mediated DNA double strand breaks induced in proliferating bystander cells after α-particle irradiation,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 684, no. 1-2, pp. 81–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. André, A. Tesniere, and G. Kroemer, “The anticancer immune response: indispensable for therapeutic success?” The Journal of Clinical Investigation, vol. 118, no. 6, pp. 1991–2001, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Fonseca and G. Dranoff, “Capitalizing on the immunogenicity of dying tumor cells,” Clinical Cancer Research, vol. 14, no. 6, pp. 1603–1608, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Kono and K. L. Rock, “How dying cells alert the immune system to danger,” Nature Reviews Immunology, vol. 8, no. 4, pp. 279–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. W. Hodge, C. Guha, J. Neefjes, and J. L. Gulley, “Synergizing radiation therapy and immunotherapy for curing incurable cancers: opportunities and challenges,” Oncology, vol. 22, no. 9, pp. 1064–1084, 2008. View at Google Scholar · View at Scopus
  8. T. Hagemann, F. Balkwill, and T. Lawrence, “Inflammation and cancer: a double-edged sword,” Cancer Cell, vol. 12, no. 4, pp. 300–301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. F. Curtin, N. Liu, M. Candolfi et al., “HMGB1 mediates endogenous TLR2 activation and brain tumor regression,” PLoS Medicine, vol. 6, no. 1, article e10, 2009. View at Google Scholar · View at Scopus
  10. S. R. Wedge, J. K. Porteous, M. G. Glaser, K. Marcus, and E. S. Newlands, “In vitro evaluation of temozolomide combined with X-irradiation,” Anti-Cancer Drugs, vol. 8, no. 1, pp. 92–97, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. W. J. Kil, D. Cerna, W. E. Burgan et al., “In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide,” Clinical Cancer Research, vol. 14, no. 3, pp. 931–938, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Kepp, L. Galluzzi, I. Martins et al., “Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy,” Cancer and Metastasis Reviews, vol. 30, no. 1, pp. 61–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. K. Calderwood, J. R. Theriault, and J. Gong, “Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity,” European Journal of Immunology, vol. 35, no. 9, pp. 2518–2527, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. D. R. Ciocca, V. R. Rozados, F. D. Cuello Carrion, S. I. Gervasoni, P. Matar, and O. G. Scharovsky, “Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin,” Cell Stress and Chaperones, vol. 8, pp. 26–36, 2003. View at Google Scholar
  15. M. Gehrmann, J. Radons, M. Molls, and G. Multhoff, “The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells,” Cell Stress and Chaperones, vol. 13, no. 1, pp. 1–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Brondani Da Rocha, A. Regner, I. Grivicich et al., “Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines,” International Journal of Oncology, vol. 25, no. 3, pp. 777–785, 2004. View at Google Scholar
  17. A. Paolini, F. Pasi, A. Facoetti et al., “Cell death forms and HSP70 expression in U87 cells after ionizing radiation and/or chemotherapy,” Anticancer Research, vol. 31, no. 11, pp. 3727–3731, 2011. View at Google Scholar · View at Scopus
  18. J. van Rijn, J. J. Heimans, J. van den Berg, P. van der Valk, and B. J. Slotman, “Survival of human glioma cells treated with various combination of temozolomide and X-rays,” International Journal of Radiation Oncology, Biology, Physics, vol. 47, no. 3, pp. 779–84, 2000. View at Publisher · View at Google Scholar
  19. J. E. Ellerman, C. K. Brown, M. de Vera et al., “Masquerader: high mobility group box-1 and cancer,” Clinical Cancer Research, vol. 13, no. 10, pp. 2836–2848, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. S. Park, J. Arcaroli, H. K. Yum et al., “Activation of gene expression in human neutrophils by high mobility group box 1 protein,” The American Journal of Physiology: Cell Physiology, vol. 284, no. 4, pp. C870–C879, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Stros, T. Ozaki, A. Bacikova, H. Kageyama, and A. Nakagawara, “HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter,” The Journal of Biological Chemistry, vol. 277, no. 9, pp. 7157–7164, 2002. View at Google Scholar
  22. P. Rovere-Querini, A. Capobianco, P. Scaffidi et al., “HMGB1 is an endogenous immune adjuvant released by necrotic cells,” EMBO Reports, vol. 5, no. 8, pp. 825–830, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. C. W. Bell, W. Jiang, C. F. Reich III, and D. S. Pisetsky, “The extracellular release of HMGB1 during apoptotic cell death,” American Journal of Physiology—Cell Physiology, vol. 291, no. 6, pp. C1318–C1325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Apetoh, F. Ghiringhelli, A. Tesniere et al., “The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy,” Immunological Reviews, vol. 220, no. 1, pp. 47–59, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Tesniere, L. Apetoh, F. Ghiringhelli et al., “Immunogenic cancer cell death: a key-lock paradigm,” Current Opinion in Immunology, vol. 20, no. 5, pp. 504–511, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Bassi, P. Giussani, V. Anelli et al., “HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration,” Journal of Neuro-Oncology, vol. 87, no. 1, pp. 23–33, 2008. View at Google Scholar
  27. A. J. Chalmers, E. M. Ruff, C. Martindale, N. Lovegrove, and S. C. Short, “Cytotoxic effects of TMZ and radiation are additive- and schedule-dependent,” International Journal of Radiation Oncology Biology Physics, vol. 75, no. 5, pp. 1511–1519, 2009. View at Publisher · View at Google Scholar · View at Scopus